Exhibit 10.22

SECURITY AGREEMENT

THIS SECURITY AGREEMENT, dated
as of November 17, 2010 (this Agreement), is by and among Accentia Biopharmaceuticals, Inc., a Florida corporation (the Company or the Debtor), and the holders of the Companys 8.50%
Secured Convertible Debentures Due November 17, 2013 (collectively, the Debentures) signatory hereto, their endorsees, transferees and assigns (collectively, the Secured Parties).

W I T N E S S E T H:

WHEREAS, the Secured Parties are existing secured creditors of the Company;

WHEREAS, pursuant to the Plan (as defined below), the Company has issued the Debentures to the Secured Parties; and

WHEREAS, the Plan provides that the Company shall grant the Secured Parties a security interest in certain property of
the Company to secure the prompt payment, performance and discharge in full of all of the Companys obligations under the Debentures.

NOW, THEREFORE, in consideration of the agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby
agree as follows:

1. Certain Definitions. As used in this Agreement, the following terms shall have
the meanings set forth in this Section 1. Terms used but not otherwise defined in this Agreement shall have the meanings set forth in the Debentures, provided that terms used but not otherwise defined herein that are defined in Article 9 of the
UCC (such as account, chattel paper, commercial tort claim, deposit account, document, equipment, fixtures, general intangibles, goods,
instruments, inventory, investment property, letter-of-credit rights, proceeds and supporting obligations) shall have the respective meanings given such terms in Article 9 of
the UCC.

(a) Agent has the meaning ascribed to such term in Section 18
of this Agreement.

(b) Bankruptcy Case means, collectively, the cases of
the Company and its Subsidiaries pending before the Bankruptcy Court under Chapter 11 of the Bankruptcy Code, and jointly administered under Case No. 8:08-bk-17795-KRM.

(c) Bankruptcy Code means title 11 of the United States Code, 11 U.S.C. §§
101 et seq.

(d) Bankruptcy Court means the United States
Bankruptcy Court for the Middle District of Florida, Tampa Division.



1



---

(e) Collateral means the Debtors
rights, titles and interest in the Debtors Revimmune assets including the Debtors Intellectual Property and assets related to Revimmune, whether presently owned or existing or hereafter acquired or coming into existence, wherever
situated, and all additions and accessions thereto and all substitutions and replacements thereof, and all proceeds, products and accounts thereof, including, without limitation, all proceeds from the sale or transfer of the Collateral and of
insurance covering the same and of any tort claims in connection therewith, including:

(i) All
contract rights and license rights and other general intangibles related to Revimmune, including, without limitation, all licenses, distribution and other agreements, computer software (whether off-the-shelf, licensed from any third
party or developed by the Debtor), computer software development rights, leases, franchises, customer lists, quality control procedures, grants and rights, goodwill, trademarks, service marks, trade styles, trade names, patents, patent applications,
copyrights, and income tax refunds;

(ii) All accounts, together with all instruments, and all
documents of title related to or representing Revimmune;

(iii) All commercial tort claims
related to Revimmune;

(iv) All deposit accounts and all cash (whether or not deposited in such
deposit accounts) relating to or resulting from Revimmune;

(v) All supporting obligations
related to Revimmune;

(vi) All files, records, books of account, business papers, and computer
programs related to the Intellectual Property; and

(vii) The products and proceeds of all of
the foregoing Collateral set forth in clauses (i)-(vi) above.

Notwithstanding the
foregoing, nothing herein shall be deemed to constitute an assignment of any asset which, in the event of an assignment, becomes void by operation of applicable law or the assignment of which is otherwise prohibited by applicable law (in each case
to the extent that such applicable law is not overridden by Sections 9-406, 9-407 and/or 9-408 of the UCC or other similar applicable law); provided, however, that to the extent permitted by applicable law, this Agreement shall create
a valid security interest in such asset and, to the extent permitted by applicable law, this Agreement shall create a valid security interest in the proceeds of such asset.

(f) Intellectual Property means the collective reference to all rights, priorities and
privileges relating to intellectual property related to Revimmune, whether arising under United States, multinational or foreign laws or otherwise, including, without limitation, (i) all copyrights arising under the laws of the United States,
any other country or any political subdivision thereof, whether registered or unregistered and



2



---

whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation, all registrations, recordings and
applications in the United States Copyright Office, (ii) all letters patent of the United States, any other country or any political subdivision thereof, all reissues and extensions thereof, and all applications for letters patent of the United
States or any other country and all divisions, continuations and continuations-in-part thereof, (iii) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade dress, service marks, logos,
domain names and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the
United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, and all common law rights related thereto, (iv) all
trade secrets arising under the laws of the United States, any other country or any political subdivision thereof, (v) all rights to obtain any reissues, renewals or extensions of the foregoing, (vi) all licenses for any of the foregoing,
and (vii) all causes of action for infringement of the foregoing.

(g) Majority
in Interest means, at any time of determination, the majority in interest (based on then outstanding principal amounts of Debentures at the time of such determination) of the Secured Parties.

(h) Necessary Endorsement means proper instruments of assignment duly executed and such
other instruments or documents as the Agent may reasonably request.

(i)
Obligations means all of the liabilities and obligations (primary, secondary, direct, contingent, sole, joint or several) due or to become due, or owing, of the Debtor to the Secured Parties under this Agreement, the Debentures,
and any other instruments, agreements or other documents executed and/or delivered in connection herewith or therewith, in each case, whether now or hereafter existing, voluntary or involuntary, direct or indirect, absolute or contingent, liquidated
or unliquidated, whether or not jointly owed with others, and whether or not from time to time decreased or extinguished and later increased, created or incurred, and all or any portion of such obligations or liabilities that are paid, to the extent
all or any part of such payment is avoided or recovered directly or indirectly from any of the Secured Parties as a preference, fraudulent transfer or otherwise, as such obligations may be amended, supplemented, converted, extended or modified from
time to time. Without limiting the generality of the foregoing, the term Obligations shall include, without limitation: (i) principal of and interest on the Debentures and the loans extended pursuant thereto; (ii) any and all
other fees, indemnities, costs, obligations and liabilities of the Debtor from time to time under or in connection with this Agreement, the Debentures, and any other instruments, agreements or other documents executed and/or delivered in connection
herewith or therewith; and (iii) all amounts (including but not limited to post-petition interest) in respect of the foregoing that would be payable but for the fact that the obligations to pay such amounts are unenforceable or not allowable
due to the existence of a bankruptcy, reorganization or similar proceeding involving the Debtor.



3



---

(j) Organizational Documents means with
respect to the Debtor, the documents by which the Debtor was organized (such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without limitation, any certificates of designation for
preferred stock or other forms of preferred equity) and which relate to the internal governance of the Debtor (such as bylaws, a partnership agreement or an operating, limited liability or members agreement).

(k) Plan means the First Amended Joint Plan of Reorganization of Accentia
Biopharmaceuticals, Inc., Analytica International, Inc., TEAMM Pharmaceuticals, Inc., AccentRx, Inc., and Accentia Specialty Pharmacy, Inc. under Chapter 11 of Title 11, United States Code dated as of August 16, 2010, as modified by the First
Modification to First Amended Joint Plan of Reorganization of Accentia Biopharmaceuticals, Inc., Analytica International, Inc., TEAMM Pharmaceuticals, Inc., AccentRx, Inc., and Accentia Specialty Pharmacy, Inc. under Chapter 11 of Title 11, United
States Code dated as of October 25, 2010 and as further modified from time to time, as filed in the Bankruptcy Case.

(l) UCC means the Uniform Commercial Code of the State of New York and any other applicable law of any state or states which has or have jurisdiction with respect to all, or any
portion, of the Collateral or this Agreement, from time to time. It is the intent of the parties that defined terms in the UCC should be construed in their broadest sense so that the term Collateral will be construed in its broadest
sense. Accordingly, if there are, from time to time, changes to defined terms in the UCC that broaden the definitions, they are incorporated herein and, if existing definitions in the UCC are broader than the amended definitions, the existing ones
shall be controlling.

2. Grant of Security Interest in Collateral. As an inducement for the Secured
Parties to extend the loans as evidenced by the Debentures and to secure the complete and timely payment, performance and discharge in full, as the case may be, of all of the Obligations, the Debtor hereby unconditionally and irrevocably pledges,
grants and hypothecates to the Secured Parties a security interest in and to, a lien upon and a right of set-off against all of its right, title and interest of whatsoever kind and nature in and to, the Collateral (a Security
Interest and, collectively, the Security Interests).

3. Delivery of Certain
Collateral. Contemporaneously or prior to the execution of this Agreement, the Debtor shall deliver or cause to be delivered to the Agent any and all certificates and other instruments or documents representing any of the applicable Collateral,
in each case, together with all Necessary Endorsements.

4. Representations, Warranties, Covenants and
Agreements of the Debtor. Except as set forth under the corresponding section of the disclosure schedules delivered to the Secured Parties concurrently herewith (the Disclosure Schedules), which Disclosure Schedules shall be
deemed a part hereof, the Debtor represents and warrants to, and covenants and agrees with, the Secured Parties as follows:



4



---

(a) The Debtor has the requisite corporate power and
authority to enter into this Agreement and otherwise to carry out its obligations hereunder. The execution, delivery and performance by the Debtor of this Agreement and the filings contemplated herein have been duly authorized by all necessary
action on the part of the Debtor and no further action is required by the Debtor. This Agreement has been duly executed by the Debtor. This Agreement constitutes the legal, valid and binding obligation of the Debtor, enforceable against the Debtor
in accordance with its terms except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization and similar laws of general application relating to or affecting the rights and remedies of creditors and by general
principles of equity.

(b) The Debtor has no place of business or offices where its books of
account and records are kept (other than temporarily at the offices of its attorneys or accountants) or places where Collateral is stored or located, except as set forth on Schedule Aattached hereto. None of such Collateral is in the
possession of any consignee, bailee, warehouseman, agent or processor.

(c) Except as set forth
on Schedule B attached hereto, the Debtor is the sole owner of the Collateral (except for licenses granted by the Debtor in the ordinary course of its business), free and clear of any liens, security interests, encumbrances, rights or claims,
and the Debtor is fully authorized to grant the Security Interests. Except as set forth on Schedule C attached hereto, there is not on file in any governmental or regulatory authority, agency or recording office an effective financing
statement, security agreement, license or transfer or any notice of any of the foregoing (other than those that will be filed in favor of the Secured Parties pursuant to this Agreement) covering or affecting any of the Collateral. Except as set
forth on Schedule C attached hereto and except pursuant to this Agreement, as long as this Agreement shall be in effect, the Debtor shall not execute and shall not knowingly permit to be on file in any such office or agency any other
financing statement or other document or instrument (except to the extent filed or recorded in favor of the Secured Parties pursuant to the terms of this Agreement).

(d) No written claim has been received by the Debtor that any Collateral or the Debtors use of any
Collateral violates the rights of any third party. There has been no adverse decision to the Debtors claim of ownership rights in or exclusive rights to use the Collateral in any jurisdiction or to the Debtors right to keep and maintain
such Collateral in full force and effect, and there is no proceeding involving said rights pending or, to the best knowledge of the Debtor, threatened before any court, judicial body, administrative or regulatory agency, arbitrator or other
governmental authority.

(e) The Debtor shall at all times maintain its books of account and
records relating to the Collateral at its principal place of business and the Collateral at the locations set forth on Schedule A attached hereto and may not relocate such books of account and records or tangible Collateral unless it delivers
to the Secured Parties at least 30 days prior to such relocation (i) written notice of such relocation and the new location thereof (which must be within the United States) and (ii) evidence that appropriate



5



---

financing statements under the UCC and other necessary documents have been filed and recorded and other steps have been taken to perfect the Security Interests and to create in favor of the
Secured Parties a valid, perfected and continuing perfected first priority lien in the Collateral.

(f) This Agreement creates in favor of the Secured Parties a valid security interest in the Collateral securing the payment and performance of the Obligations. Upon making the filings described in the
immediately following paragraph, all security interests created hereunder in any Collateral which may be perfected by filing Uniform Commercial Code financing statements shall have been duly perfected. Except for the filing of the Uniform Commercial
Code financing statements referred to in the immediately following paragraph, the recordation of the Intellectual Property Security Agreement (as defined in Section 4(n) hereof) with respect to copyrights and copyright applications in the
United States Copyright Office referred to in Section 4 (gg) hereof, the execution and delivery of deposit account control agreements satisfying the requirements of Section 9-104(a)(2) of the UCC with respect to each deposit account of the
Debtor, and the delivery of the certificates and other instruments provided in Section 3, no action is necessary to create, perfect or protect the Security Interests created hereunder. Without limiting the generality of the foregoing, except
for the filing of said financing statements, the recordation of said Intellectual Property Security Agreement, and the execution and delivery of said deposit account control agreements, no consent of any third parties and no authorization, approval
or other action by, and no notice to or filing with, any governmental authority or regulatory body is required for (i) the execution, delivery and performance of this Agreement, (ii) the creation or perfection of the Security Interests
created hereunder in the Collateral or (iii) the enforcement of the rights of the Agent and the Secured Parties hereunder.

(g) The Debtor hereby authorizes the Agent to file one or more financing statements under the UCC, with respect to the Security Interests, with the proper filing and recording agencies in any jurisdiction
deemed proper by the Agent.

(h) The execution, delivery and performance of this Agreement by
the Debtor does not (i) violate any of the provisions of any Organizational Documents of the Debtor or any judgment, decree, order or award of any court, governmental body or arbitrator or any applicable law, rule or regulation applicable to
the Debtor or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing the Debtors debt or otherwise) or other understanding to which the Debtor is a party or by which any property or asset of the
Debtor is bound or affected. All required consents (including, without limitation, from stockholders or creditors of the Debtor) necessary for the Debtor to enter into and perform its obligations hereunder have been obtained.

(i) The Debtor shall at all times maintain the liens and Security Interests provided for hereunder as
valid and perfected first priority liens and security interests in



6



---

the Collateral in favor of the Secured Parties until this Agreement and the Security Interest hereunder shall be terminated pursuant to Section 14 hereof. The Debtor hereby agrees to defend
the same against the claims of any and all persons and entities. The Debtor shall safeguard and protect all Collateral for the account of the Secured Parties. At the request of the Agent, the Debtor will sign and deliver to the Agent on behalf of
the Secured Parties at any time or from time to time one or more financing statements pursuant to the UCC in form reasonably satisfactory to the Agent and will pay the cost of filing the same in all public offices wherever filing is, or is deemed by
the Agent to be, necessary or desirable to effect the rights and obligations provided for herein. Without limiting the generality of the foregoing, the Debtor shall pay all fees, taxes and other amounts necessary to maintain the Collateral and the
Security Interests hereunder, and the Debtor shall obtain and furnish to the Agent from time to time, upon demand, such releases and/or subordinations of claims and liens which may be required to maintain the priority of the Security Interests
hereunder.

(j) The Debtor will not transfer, license, pledge, hypothecate, encumber, sell or
otherwise dispose of any of the Collateral (except for licenses or sublicenses granted or that may be granted by the Debtor in the ordinary course of its business) without the prior written consent of a Majority in Interest.

(k) The Debtor shall keep and preserve its equipment, inventory and other tangible Collateral in good
condition, repair and order and shall not operate or locate (or cause to be operated or located) any such Collateral in any area excluded from insurance coverage.

(l) The Debtor shall maintain with financially sound and reputable insurers, insurance with respect to the
Collateral, including Collateral hereafter acquired, against loss or damage of the kinds and in the amounts customarily insured against by entities of established reputation having similar properties similarly situated and in such amounts as are
customarily carried under similar circumstances by other such entities and otherwise as is prudent for entities engaged in similar businesses but in any event sufficient to cover the full replacement cost thereof. The Debtor shall cause each
insurance policy issued in connection herewith to provide, and the insurer issuing such policy to certify to the Agent, that (a) the Agent will be named as lender loss payee and additional insured under each such insurance policy; (b) if
such insurance be proposed to be cancelled or materially changed for any reason whatsoever, such insurer will promptly notify the Agent and such cancellation or change shall not be effective as to the Agent for at least thirty (30) days after
receipt by the Agent of such notice, unless the effect of such change is to extend or increase coverage under the policy; and (c) the Agent will have the right (but no obligation) at its election to remedy any default in the payment of premiums
within thirty (30) days of notice from the insurer of such default. If no Event of Default (as defined in the Debentures) exists and if the proceeds arising out of any claim or series of related claims do not exceed $100,000, loss payments in
each instance will be applied by the Debtor to the repair and/or replacement of property with respect to which the loss was incurred to the extent reasonably feasible, and any loss payments or the balance thereof remaining, to the extent not so
applied, shall be payable to the Debtor; provided,



7



---

however, that payments received by the Debtor after an Event of Default occurs and is continuing or in excess of $100,000 for any occurrence or series of related occurrences shall be paid to the
Agent on behalf of the Secured Parties and, if received by the Debtor, shall be held in trust for the Secured Parties and immediately paid over to the Agent unless otherwise directed in writing by the Agent. Copies of such policies or the related
certificates, in each case, naming the Agent as lender loss payee and additional insured shall be delivered to the Agent at least annually and at the time any new policy of insurance is issued.

(m) The Debtor shall, within ten (10) days of obtaining knowledge thereof, advise the Secured Parties
promptly, in sufficient detail and through the Agent, of any material adverse change in the Collateral, and of the occurrence of any event which would have a material adverse effect on the value of the Collateral or on the Security Interests
therein.

(n) The Debtor shall promptly execute and deliver to the Agent such further security
agreements, financing statements or other instruments, documents, certificates and assurances and take such further action as the Agent may from time to time request and may in its sole discretion deem necessary to perfect, protect or enforce the
Security Interests in the Collateral including, without limitation, if applicable, the execution and delivery of a separate security agreement with respect to the Debtors Intellectual Property (Intellectual Property Security
Agreement) in which the Secured Parties have been granted a security interest hereunder, substantially in a form reasonably acceptable to the Agent, which Intellectual Property Security Agreement, other than as stated therein, shall be
subject to all of the terms and conditions hereof.

(o) The Debtor shall permit the Agent and
its representatives and agents to inspect the Collateral during normal business hours and upon reasonable prior notice, and to make copies of records pertaining to the Collateral as may be reasonably requested by the Agent from time to time.

(p) The Debtor shall take all steps reasonably necessary to diligently pursue and seek to
preserve, enforce and collect any rights, claims, causes of action and accounts receivable in respect of the Collateral.

(q) The Debtor shall promptly notify the Secured Parties in sufficient detail upon becoming aware of any attachment, garnishment, execution or other legal process levied against any Collateral and of any
other information received by the Debtor that may materially affect the value of the Collateral, the Security Interests or the rights and remedies of the Secured Parties hereunder.

(r) All information heretofore, herein or hereafter supplied to the Secured Parties by or on behalf of the
Debtor with respect to the Collateral is or will be accurate and complete in all material respects as of the date furnished.



8



---

(s) The Debtor shall at all times preserve and keep in full
force and effect its valid existence and good standing and any rights and franchises material to its business.

(t) The Debtor will not change its name, type of organization, jurisdiction of organization, organizational identification number (if it has one), legal or corporate structure, or identity, or add any new
fictitious name unless it provides at least 30 days prior written notice to the Secured Parties of such change and, at the time of such written notification, the Debtor provides any financing statements or fixture filings necessary to perfect and
continue the perfection of the Security Interests granted and evidenced by this Agreement.

(u)
Except in the ordinary course of business, the Debtor may not consign any of its inventory or sell any of its inventory on bill and hold, sale or return, sale on approval, or other conditional terms of sale without the consent of the Agent which
shall not be unreasonably withheld.

(v) The Debtor may not relocate its chief executive office
to a new location without providing 30 days prior written notification thereof to the Secured Parties and so long as, at the time of such written notification, the Debtor provides any financing statements or fixture filings necessary to perfect and
continue the perfection of the Security Interests granted and evidenced by this Agreement.

(w)
The Debtor was organized and remains organized solely under the laws of the state set forth next to the Debtors name in Schedule D attached hereto, which Schedule D sets forth the Debtors organizational identification
number or, if the Debtor does not have one, states that one does not exist.

(x) (i) The
actual name of the Debtor is the name set forth in Schedule E attached hereto; (ii) the Debtor has no trade names except as set forth on Schedule E attached hereto; (iii) the Debtor has not used any name other than as set
forth on Schedule E for the preceding five years; and (iv) no entity has merged into the Debtor or been acquired by the Debtor within the past five years except as set forth on Schedule E.

(y) At any time and from time to time that any Collateral consists of instruments, certificated securities
or other items that require or permit possession by the secured party to perfect the security interest created hereby, the Debtor shall deliver such Collateral to the Agent.

(z) The Debtor shall cause all tangible chattel paper constituting Collateral to be delivered to the
Agent, or, if such delivery is not possible, then to cause such tangible chattel paper to contain a legend noting that it is subject to the Security Interest created by this Agreement. To the extent that any Collateral consists of electronic chattel
paper, the Debtor shall cause the underlying chattel paper to be marked within the meaning of Section 9-105 of the UCC (or successor section thereto).



9



---

(aa) If there is any investment property or deposit account
included as Collateral that can be perfected by control through an account control agreement, the Debtor shall cause such an account control agreement, in form and substance in each case satisfactory to the Agent, to be entered into and
delivered to the Agent for the benefit of the Secured Parties.

(bb) To the extent that any
Collateral consists of letter-of-credit rights, the Debtor shall cause the issuer of each underlying letter of credit to consent to an assignment of the proceeds thereof to the Secured Parties.

(cc) To the extent that any Collateral is in the possession of any third party, the Debtor shall join with
the Agent in notifying such third party of the Secured Parties security interest in such Collateral and shall use its best efforts to obtain an acknowledgement and agreement from such third party with respect to the Collateral, in form and
substance reasonably satisfactory to the Agent.

(dd) If the Debtor shall at any time hold or
acquire a commercial tort claim constituting Collateral, the Debtor shall promptly notify the Secured Parties in a writing signed by the Debtor of the particulars thereof and grant to the Secured Parties in such writing a security interest therein
and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance satisfactory to the Agent.

(ee) The Debtor shall immediately provide written notice to the Secured Parties of any and all accounts constituting Collateral which arise out of contracts with any governmental authority and, to the
extent necessary to perfect or continue the perfected status of the Security Interests in such accounts and proceeds thereof, shall execute and deliver to the Agent an assignment of claims for such accounts and cooperate with the Agent in taking any
other steps required, in the judgment of the Agent, under the Federal Assignment of Claims Act or any similar federal, state or local statute or rule to perfect or continue the perfected status of the Security Interests in such accounts and proceeds
thereof.

(ff) The Debtor shall cause each subsidiary of the Debtor that has any interest in
the Collateral to immediately become a party hereto (an Additional Debtor), by executing and delivering an Additional Debtor Joinder in substantially the form of Annex A attached hereto, and comply with the provisions
hereof applicable to the Debtor. Concurrent therewith, the Additional Debtor shall deliver replacement schedules for, or supplements to, all Disclosure Schedules to (or referred to in) this Agreement, as applicable, which replacement schedules shall
supersede, or supplements shall modify, the Disclosure Schedules then in effect. The Additional Debtor shall also deliver such opinions of counsel, authorizing resolutions, good standing certificates, incumbency certificates, organizational
documents, financing statements and other information and documentation as the Agent may reasonably request. Upon delivery of the foregoing to the Agent, the Additional Debtor shall be and become a party to this Agreement with the same rights and
obligations as the Debtor, for all purposes hereof as fully and to the same extent as if it were an original signatory hereto and shall be deemed to have made the



10



---

representations, warranties and covenants set forth herein as of the date of execution and delivery of such Additional Debtor Joinder, and all references herein to the Debtor shall be
deemed to include each Additional Debtor.

(gg) Without limiting the generality of the other
obligations of the Debtor hereunder, the Debtor shall promptly (i) cause to be registered at the United States Copyright Office all of its material copyrights related to Revimmune, except where the Debtor decides not to register such copyrights
for business or legal reasons on the advice of counsel, (ii) cause the Security Interest contemplated hereby with respect to all Intellectual Property registered at the United States Copyright Office or United States Patent and Trademark Office
to be duly recorded at the applicable office, except for intent-to-use trademark applications in which no statement of use has yet been filed, and (iii) give the Agent notice whenever it acquires (whether absolutely or by license) or creates
any additional material Intellectual Property.

(hh) The Debtor will from time to time, at the
Debtors expense, promptly execute and deliver all such further instruments and documents, and take all such further action as may be necessary or desirable, or as the Agent may reasonably request, in order to perfect and protect any security
interest granted or purported to be granted hereby or to enable the Secured Parties to exercise and enforce their rights and remedies hereunder and with respect to any Collateral or to otherwise carry out the purposes of this Agreement.

(ii) Schedule F attached hereto lists all of the patents, patent applications, trademarks,
trademark applications, registered copyrights, and domain names owned by the Debtor and related to Revimmune, as of the date hereof. Schedule F lists all material licenses in favor of the Debtor for the use of any patents, trademarks,
copyrights and domain names related to Revimmune as of the date hereof. All material patents and trademarks of the Debtor related to Revimmune have been filed at the United States Patent and Trademark Office and all material copyrights of the Debtor
related to Revimmune have been duly recorded at the United States Copyright Office, except where the Debtor has decided, for business or legal reasons on the advice of counsel, that a copyright registration shall not be filed.

(jj) Except as set forth on Schedule G attached hereto, none of the account debtors or other
persons or entities obligated on any of the Collateral is a governmental authority covered by the Federal Assignment of Claims Act or any similar federal, state or local statute or rule in respect of such Collateral.

5. Effect of Pledge on Certain Rights. If any of the Collateral subject to this Agreement consists of nonvoting
equity or ownership interests (regardless of class, designation, preference or rights) that may be converted into voting equity or ownership interests upon the occurrence of certain events (including, without limitation, upon the transfer of all or
any of the other stock or assets of the issuer), it is agreed that the pledge of such equity or ownership interests pursuant to this Agreement or the enforcement of any of Agents rights hereunder shall not be deemed to be the type of event
which would trigger such conversion rights



11



---

notwithstanding any provisions in the Organizational Documents or agreements to which the Debtor is subject or to which the Debtor is party.

6. Defaults. The following events shall be Events of Default:

(a) The occurrence of an Event of Default (as defined in the Debentures) under the Debentures;

(b) Any representation or warranty of the Debtor in this Agreement shall prove to have been
incorrect in any material respect when made;

(c) The failure by the Debtor to observe or
perform any of its obligations hereunder for five (5) business days after delivery to the Debtor of notice of such failure by or on behalf of a Secured Party unless such default is capable of cure but cannot be cured within such time frame and
the Debtor is using best efforts to cure same in a timely fashion; or

(d) If any provision of
this Agreement shall at any time for any reason be declared to be null and void, or the validity or enforceability thereof shall be contested by the Debtor, or a proceeding shall be commenced by the Debtor, or by any governmental authority having
jurisdiction over the Debtor, seeking to establish the invalidity or unenforceability thereof, or the Debtor shall deny that the Debtor has any liability or obligation purported to be created under this Agreement.

7. Duty To Hold In Trust. Upon the occurrence of any Event of Default and at any time thereafter, the Debtor
shall, upon receipt of any revenue, income, dividend, interest or other sums subject to the Security Interests, whether payable pursuant to the Debentures or otherwise, or of any check, draft, note, trade acceptance or other instrument evidencing an
obligation to pay any such sum, hold the same in trust for the Secured Parties and shall forthwith endorse and transfer any such sums or instruments, or both, to the Secured Parties, pro-rata in proportion to their respective then currently
outstanding principal amount of Debentures for application to the satisfaction of the Obligations (and if any Debenture is not outstanding, pro-rata in proportion to the initial purchased principal amount of the remaining Debentures).

8. Rights and Remedies Upon Default.

(a) Upon the occurrence of any Event of Default and at any time thereafter, the Secured Parties, acting
through the Agent, shall have the right to exercise all of the remedies conferred hereunder and under the Debentures, and the Secured Parties shall have all the rights and remedies of a secured party under the UCC. Without limitation, the Agent, for
the benefit of the Secured Parties, shall have the following rights and powers:

(i) The Agent
shall have the right to take possession of the Collateral and, for that purpose, enter, with the aid and assistance of any person, any premises where the Collateral, or any part thereof, is or may be placed and



12



---

remove the same, and the Debtor shall assemble the Collateral and make it available to the Agent at places which the Agent shall reasonably select, whether at the Debtors premises or
elsewhere, and make available to the Agent, without rent, all of the Debtors premises and facilities for the purpose of the Agent taking possession of, removing or putting the Collateral in saleable or disposable form.

(ii) Upon notice to the Debtor by Agent, all rights of the Debtor to exercise the voting and other
consensual rights which it would otherwise be entitled to exercise and all rights of the Debtor to receive the dividends and interest which it would otherwise be authorized to receive and retain, in each case with respect to the Collateral, shall
cease. Upon such notice, Agent shall have the right to receive, for the benefit of the Secured Parties, any interest, cash dividends or other payments on the Collateral and, at the option of Agent, to exercise in such Agents discretion all
voting rights pertaining thereto. Without limiting the generality of the foregoing, Agent shall have the right (but not the obligation) to exercise all rights with respect to the Collateral as if it were the sole and absolute owner thereof,
including, without limitation, to vote and/or to exchange, at its sole discretion, any or all of the Collateral in connection with a merger, reorganization, consolidation, recapitalization or other readjustment concerning or involving the Collateral
or the Debtor or any of its direct or indirect subsidiaries.

(iii) The Agent shall have the
right to operate the business of the Debtor using the Collateral and shall have the right to assign, sell, lease or otherwise dispose of and deliver all or any part of the Collateral (except with respect to any license, subject to the terms of such
license), at public or private sale or otherwise, either with or without special conditions or stipulations, for cash or on credit or for future delivery, in such parcel or parcels and at such time or times and at such place or places, and upon such
terms and conditions as the Agent may deem commercially reasonable, all without (except as shall be required by applicable statute and cannot be waived) advertisement or demand upon or notice to the Debtor or right of redemption of the Debtor, which
are hereby expressly waived. Upon each such sale, lease, assignment or other transfer of Collateral, the Agent, for the benefit of the Secured Parties, may, unless prohibited by applicable law which cannot be waived, or by the applicable license or
agreement, purchase all or any part of the Collateral being sold, free from and discharged of all trusts, claims, right of redemption and equities of the Debtor, which are hereby waived and released.

(iv) The Agent shall have the right (but not the obligation) to notify any account debtors and any
obligors under instruments or accounts relating to the Collateral to make payments directly to the Agent, on behalf of the Secured Parties, and to enforce the Debtors rights against such account debtors and obligors.

(v) The Agent, for the benefit of the Secured Parties, may (but is not obligated to) direct any financial
intermediary or any other person or entity



13



---

holding any investment property relating to the Collateral to transfer the same to the Agent, on behalf of the Secured Parties, or its designee.

(vi) The Agent may (but is not obligated to) transfer any or all Intellectual Property relating to the
Collateral registered in the name of the Debtor at the United States Patent and Trademark Office and/or Copyright Office into the name of the Secured Parties or any designee or any purchaser of any Collateral.

(b) The Agent shall comply with any applicable law in connection with a disposition of the Collateral and
such compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. The Agent may sell the Collateral without giving any warranties and may specifically disclaim such warranties. If the Agent sells
any of the Collateral on credit, the Debtor will only be credited with payments actually made by the purchaser. In addition, the Debtor waives any and all rights that it may have to a judicial hearing in advance of the enforcement of any of the
Agents rights and remedies hereunder, including, without limitation, its right following an Event of Default to take immediate possession of the Collateral and to exercise its rights and remedies with respect thereto.

(c) For the purpose of enabling the Agent to further exercise rights and remedies under this
Section 8 or elsewhere provided by agreement or applicable law, the Debtor hereby grants to the Agent, for the benefit of the Agent and the Secured Parties, an irrevocable, nonexclusive license (exercisable without payment of royalty or other
compensation to the Debtor) to use, license or sublicense, following an Event of Default, any Intellectual Property relating to the Collateral now owned or hereafter acquired by the Debtor, and wherever the same may be located, and including in such
license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof.

9. Applications of Proceeds. The proceeds of any such sale, lease or other disposition of the Collateral hereunder
or from payments made on account of any insurance policy insuring any portion of the Collateral shall be applied first, to the expenses of retaking, holding, storing, processing and preparing for sale, selling, and the like (including, without
limitation, any taxes, fees and other costs incurred in connection therewith) of the Collateral, to the reasonable attorneys fees and expenses incurred by the Agent in enforcing the Secured Parties rights hereunder and in connection with
collecting, storing and disposing of the Collateral, and then to satisfaction of the Obligations pro rata among the Secured Parties (based on then outstanding principal amounts of Debentures at the time of any such determination), and to the payment
of any other amounts required by applicable law, after which the Secured Parties shall pay to the Debtor any surplus proceeds. If, upon the sale, license or other disposition of the Collateral, the proceeds thereof are insufficient to pay all
amounts to which the Secured Parties are legally entitled, the Debtor will be liable for the deficiency, together with interest thereon, at the rate of 18% per annum or the lesser amount permitted by applicable law (the Default
Rate), and the reasonable fees of any attorneys employed by the Secured Parties to collect such deficiency. To the extent permitted by applicable law, the Debtor waives all claims, damages and demands against the Secured Parties arising
out of the repossession, removal, retention or sale of the Collateral, unless due solely to the gross negligence or willful misconduct of the



14



---

Secured Parties as determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction.

10. [RESERVED]

11. Costs and Expenses. The Debtor agrees to pay all reasonable out-of-pocket fees, costs and expenses incurred in connection with any filing required hereunder, including without limitation, any
financing statements pursuant to the UCC, continuation statements, partial releases and/or termination statements related thereto or any expenses of any searches reasonably required by the Agent. The Debtor shall also pay all other claims and
charges which in the reasonable opinion of the Agent are reasonably likely to prejudice, imperil or otherwise affect the Collateral or the Security Interests therein. The Debtor will also, upon demand, pay to the Agent the amount of any and all
reasonable expenses, including the reasonable fees and expenses of its counsel and of any experts and agents, which the Agent, for the benefit of the Secured Parties, may incur in connection with the creation, perfection, protection, satisfaction,
foreclosure, collection or enforcement of the Security Interest and the administration, continuance, amendment or enforcement of this Agreement, and pay to the Agent the amount of any and all reasonable expenses, including the reasonable fees and
expenses of its counsel and of any experts and agents, which the Agent, for the benefit of the Secured Parties, and the Secured Parties may incur in connection with (i) the enforcement of this Agreement, (ii) the custody or preservation
of, or the sale of, collection from, or other realization upon, any of the Collateral, or (iii) the exercise or enforcement of any of the rights of the Secured Parties under the Debentures. Until so paid, any fees payable hereunder shall be
added to the principal amount of the Debentures and shall bear interest at the Default Rate.

12.
Responsibility for Collateral. The Debtor assumes all liabilities and responsibility in connection with all Collateral, and the Obligations shall in no way be affected or diminished by reason of the loss, destruction, damage or theft of any
of the Collateral or its unavailability for any reason. Without limiting the generality of the foregoing, (a) neither the Agent nor any Secured Party (i) has any duty (either before or after an Event of Default) to collect any amounts in
respect of the Collateral or to preserve any rights relating to the Collateral, or (ii) has any obligation to clean-up or otherwise prepare the Collateral for sale, and (b) the Debtor shall remain obligated and liable under each contract
or agreement included in the Collateral to be observed or performed by the Debtor thereunder. Neither the Agent nor any Secured Party shall have any obligation or liability under any such contract or agreement by reason of or arising out of this
Agreement or the receipt by the Agent or any Secured Party of any payment relating to any of the Collateral, nor shall the Agent or any Secured Party be obligated in any manner to perform any of the obligations of the Debtor under or pursuant to any
such contract or agreement, to make inquiry as to the nature or sufficiency of any payment received by the Agent or any Secured Party in respect of the Collateral or as to the sufficiency of any performance by any party under any such contract or
agreement, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to the Agent or to which the Agent or any Secured Party may be entitled at any time or
times.

13. Security Interests Absolute. All rights of the Secured Parties and all obligations of the
Debtor hereunder shall be absolute and unconditional, irrespective of: (a) any lack of



15



---

validity or enforceability of this Agreement, the Debentures or any agreement entered into in connection with the foregoing, or any portion hereof or thereof; (b) any change in the time,
manner or place of payment or performance of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to any departure from the Debentures or any other agreement entered into in connection with the
foregoing; (c) any exchange, release or nonperfection of any of the Collateral, or any release or amendment or waiver of or consent to departure from any other collateral for, or any guarantee, or any other security, for all or any of the
Obligations; (d) any action by the Secured Parties to obtain, adjust, settle and cancel in their sole discretion any insurance claims or matters made or arising in connection with the Collateral; or (e) any other circumstance which might
otherwise constitute any legal or equitable defense available to the Debtor, or a discharge of all or any part of the Security Interests granted hereby. Until the Obligations shall have been paid and performed in full, the rights of the Secured
Parties shall continue even if the Obligations are barred for any reason, including, without limitation, the running of the statute of limitations or bankruptcy. The Debtor expressly waives presentment, protest, notice of protest, demand, notice of
nonpayment and demand for performance. In the event that at any time any transfer of any Collateral or any payment received by the Secured Parties hereunder shall be deemed by a final order of a court of competent jurisdiction to have been a
voidable preference or fraudulent conveyance under the bankruptcy or insolvency laws of the United States, or shall be deemed to be otherwise due to any party other than the Secured Parties, then, in any such event, the Debtors obligations
hereunder shall survive cancellation of this Agreement, and shall not be discharged or satisfied by any prior payment thereof and/or cancellation of this Agreement, but shall remain a valid and binding obligation enforceable in accordance with the
terms and provisions hereof. The Debtor waives all right to require the Secured Parties to proceed against any other person or entity or to apply any Collateral which the Secured Parties may hold at any time, or to marshal assets, or to pursue any
other remedy. The Debtor waives any defense arising by reason of the application of the statute of limitations to any obligation secured hereby.

14. Term of Agreement. This Agreement and the Security Interests shall terminate on the date on which all payments under the Debentures have been indefeasibly paid in full and all other Obligations
have been paid or discharged; provided, however, that all indemnities of the Debtor contained in this Agreement shall survive and remain operative and in full force and effect regardless of the termination of this Agreement.

15. Power of Attorney; Further Assurances.

(a) The Debtor authorizes the Agent, and does hereby make, constitute and appoint the Agent and its
officers, agents, successors or assigns with full power of substitution, as the Debtors true and lawful attorney-in-fact, with power, in the name of the Agent or the Debtor, to, after the occurrence and during the continuance of an Event of
Default, (i) endorse any note, checks, drafts, money orders or other instruments of payment (including payments payable under or in respect of any policy of insurance) in respect of the Collateral that may come into possession of the Agent;
(ii) to sign and endorse any financing statement pursuant to the UCC or any invoice, freight or express bill, bill of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with
accounts, and other documents relating to the



16



---

Collateral; (iii) to pay or discharge taxes, liens, security interests or other encumbrances at any time levied or placed on or threatened against the Collateral; (iv) to demand,
collect, receipt for, compromise, settle and sue for monies due in respect of the Collateral; (v) to transfer any Intellectual Property or provide licenses respecting any Intellectual Property, in each case relating to the Collateral; and
(vi) generally, at the option of the Agent, and at the expense of the Debtor, at any time, or from time to time, to execute and deliver any and all documents and instruments and to do all acts and things which the Agent deems necessary to
protect, preserve and realize upon the Collateral and the Security Interests granted therein in order to effect the intent of this Agreement and the Debentures all as fully and effectually as the Debtor might or could do; and the Debtor hereby
ratifies all that said attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and shall be irrevocable for the term of this Agreement and thereafter as long as any of the Obligations shall
be outstanding. The designation set forth herein shall be deemed to amend and supersede any inconsistent provision in the Organizational Documents or other documents or agreements to which the Debtor is subject or to which the Debtor is a party.
Without limiting the generality of the foregoing, after the occurrence and during the continuance of an Event of Default, each Secured Party is specifically authorized to execute and file any applications for or instruments of transfer and
assignment of any patents, trademarks, copyrights or other Intellectual Property relating to the Collateral with the United States Patent and Trademark Office and the United States Copyright Office.

(b) On a continuing basis, the Debtor will make, execute, acknowledge, deliver, file and record, as the
case may be, with the proper filing and recording agencies in any jurisdiction, all such instruments, and take all such action, as may reasonably be deemed necessary or advisable, and reasonably requested by the Agent, to perfect the Security
Interests granted hereunder and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to the Agent the grant or perfection of a perfected security interest in all the Collateral under the UCC.

(c) The Debtor hereby irrevocably appoints the Agent as the Debtors attorney-in-fact, with full
authority in the place and instead of the Debtor and in the name of the Debtor, from time to time in the Agents discretion, to take any action and to execute any instrument which the Agent may deem necessary or advisable to accomplish the
purposes of this Agreement, including the filing, in its sole discretion, of one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of the Debtor where permitted by law, and
ratifies all such actions taken by the Agent. This power of attorney is coupled with an interest and shall be irrevocable for the term of this Agreement and thereafter as long as any of the Obligations shall be outstanding.

16. Notices. All notices, requests, demands and other communications hereunder shall be subject to the notice
provision of the Debentures.



17



---

17. Other Security. To the extent that the Obligations are now or
hereafter secured by property other than the Collateral or by the guarantee, endorsement or property of any other person, firm, corporation or other entity, then the Agent shall have the right, in its sole discretion, to pursue, relinquish,
subordinate, modify or take any other action with respect thereto, without in any way modifying or affecting any of the Secured Parties rights and remedies hereunder.

18. Appointment of Agent. The Secured Parties hereby appoint Midsummer Investment Ltd. to act as their agent
(Midsummer or Agent) for purposes of exercising any and all rights and remedies of the Secured Parties hereunder. Such appointment shall continue until revoked in writing by a Majority in Interest, at which time
a Majority in Interest shall appoint a new Agent, provided that Midsummer may not be removed as Agent unless Midsummer shall then hold less than $250,000 in principal amount of Debentures; provided, further, that such removal may occur only if each
of the other Secured Parties shall then hold not less than an aggregate of $500,000 in principal amount of Debentures. The Agent shall have the rights, responsibilities and immunities set forth in Annex B hereto.

19. Miscellaneous.

(a) Notwithstanding anything to the contrary in this Agreement, the right of the Secured Parties, upon
default, to effect any sublicense or assignment of any license is subject to the terms of such license. Nothing in this Agreement creates or permits any assignment of any intent-to-use trademark application. This Agreement constitutes a
first lien in the Collateral and shall not be construed as a current assignment.

(b) No course
of dealing between the Debtor and the Secured Parties, nor any failure to exercise, nor any delay in exercising, on the part of the Secured Parties, any right, power or privilege hereunder or under the Debentures, shall operate as a waiver thereof;
nor shall any single or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

(c) All of the rights and remedies of the Secured Parties with respect to the Collateral, whether
established hereby or by the Debentures or by any other agreements, instruments or documents or by law, shall be cumulative and may be exercised singly or concurrently.

(d) This Agreement, together with the exhibits and schedules hereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement and the exhibits and
schedules hereto. Subject to Section 19(n), no provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Debtor and the Secured Parties or, in the
case of a waiver, by the party against whom enforcement of any such waived provision is sought.



18



---

(e) If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be
affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

(f) No waiver of any default with respect to any
provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of any party to exercise any right hereunder in any manner impair the exercise of any such right.

(g) This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors and permitted assigns. The Debtor may not assign this Agreement or any rights or obligations
hereunder without the prior written consent of each Secured Party (other than by merger). Any Secured Party may assign any or all of its rights under this Agreement to any Person (as defined in the Debentures) to whom such Secured Party assigns or
transfers any Obligations, provided such transferee agrees in writing to be bound, with respect to the transferred Obligations, by the provisions of this Agreement that apply to the Secured Parties.

(h) Each party shall take such further action and execute and deliver such further documents as may be
necessary or appropriate in order to carry out the provisions and purposes of this Agreement.

(i) All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. The Debtor agrees that all proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and the Debentures (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York, Borough of Manhattan. The Debtor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any proceeding, any claim that it is not
personally subject to the jurisdiction of any such court, or that such proceeding is improper. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such proceeding by mailing a copy
thereof via registered or



19



---

certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent
permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

(j) This Agreement may be executed in any number of counterparts, each of which when so executed shall be
deemed to be an original and all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party
executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof.

(k) The Debtor shall indemnify, reimburse and hold harmless the Agent and the Secured Parties and their
respective partners, members, shareholders, officers, directors, employees and agents (and any other persons with other titles that have similar functions) (collectively, Indemnitees) from and against any and all losses, claims,
liabilities, damages, penalties, suits, costs and expenses, of any kind or nature, (including fees relating to the cost of investigating and defending any of the foregoing) imposed on, incurred by or asserted against such Indemnitee in any way
related to or arising from or alleged to arise from this Agreement or the Collateral, except any such losses, claims, liabilities, damages, penalties, suits, costs and expenses which result from the gross negligence or willful misconduct of the
Indemnitee as determined by a final, nonappealable decision of a court of competent jurisdiction. This indemnification provision is in addition to, and not in limitation of, any other indemnification provision in the Debentures or any other
agreement, instrument or other document executed or delivered in connection herewith or therewith.

(l) Nothing in this Agreement shall be construed to subject Agent or any Secured Party to liability as a partner in the Debtor or any of its direct or indirect subsidiaries that is a partnership or as a
member in the Debtor or any of its direct or indirect subsidiaries that is a limited liability company, nor shall Agent or any Secured Party be deemed to have assumed any obligations under any partnership agreement or limited liability company
agreement, as applicable, of the Debtor or any of its direct or indirect subsidiaries or otherwise, unless and until any such Secured Party exercises its right to be substituted for the Debtor as a partner or member, as applicable, pursuant hereto.

(m) To the extent that the grant of the security interest in the Collateral and the
enforcement of the terms hereof require the consent, approval or action of any partner or member, as applicable, of the Debtor or any direct or indirect subsidiary of the Debtor or compliance with any provisions of any of the Organizational
Documents, the Debtor hereby grants such consent and approval and waives any such noncompliance with the terms of said documents.



20



---

(n) The provisions of this Agreement may be amended, or the
provisions hereof waived, with the prior written consent of the Debtor and the Secured Parties holding 67% or more of the aggregate principal amount of all Debentures then outstanding.

[SIGNATURE PAGES FOLLOW]



21



---

IN WITNESS WHEREOF, the parties hereto have caused this Security Agreement
to be duly executed on the day and year first above written.



|                                  |  |                                 
|--------------------------------- |  | --------------------------------
|ACCENTIA BIOPHARMACEUTICALS, INC.
|                                  | 
|By:                               |  |                                 
|                                  |  | Name: Samuel S. Duffey, Esq.    
|                                  |  | Title: President/General Counsel

[SIGNATURE PAGES OF SECURED PARTIES FOLLOW]



22



---

[SIGNATURE PAGE OF SECURED PARTY]

Name of Secured Party:

Signature of Authorized Signatory of Secured Party:

Name of Authorized Signatory:

Title of Authorized Signatory:

Address of Secured Party:



23



---

Schedule A

LOCATION OF DEBTORS BOOKS OF ACCOUNT AND RECORDS

Accentia Biopharmaceuticals, Inc.

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606



1



---

Schedule B

LIENS ON COLLATERAL

None



1



---

Schedule C

FILINGS OR RECORDATIONS IN GOVERNMENTAL OR REGULATORY AUTHORITY,

AGENCY, OR RECORDING OFFICE

On the date of the execution of this
Agreement, all security interests in the Collateral, except those granted hereby to the Secured Parties under this Agreement, will be released.



1



---

Schedule D

DEBTORS STATE OF ORGANIZATION



|                                  |  |                       |  |                       
|--------------------------------- |  | --------------------- |  | ----------------------
|Company Name                      |  | Date of Incorporation |  | State of Incorporation
|                                  |  |                      
|Accentia Biopharmaceuticals, Inc. |  | March 26, 2002        |  | Florida               
|                                  |  |                       |  | P02000033509          



1



---

Schedule E

DEBTORS NAMES

(i) The name of the Debtor is Accentia Biopharmaceuticals, Inc.

(ii) The Debtor
does not have any trade names.

(iii) Within the past five years, the Debtor used the name Accentia, Inc. (which was changed on
May 11, 2005).

(iv) No entity has merged into, or been acquired by, the Debtor within the past five years.



1



---

Schedule F

Intellectual Property Related to Revimmune; including License Rights (In-Licensed)



|              |  |         |  |         |  |               |  |        |  |             |  |                                                                                          |  |                                                                                                                 |  |                                                                |  |                                                                                                                     |  |             
|------------- |  | ------- |  | ------- |  | ------------- |  | ------ |  | ----------- |  | ---------------------------------------------------------------------------------------- |  | --------------------------------------------------------------------------------------------------------------- |  | -------------------------------------------------------------- |  | ------------------------------------------------------------------------------------------------------------------- |  | ------------
|Atty Docket # |  | Country |  | Status  |  | Application # |  | Pub. # |  | Filing
Date |  | Priority                                                                                 |  | Title                                                                                                           |  | Owner/Assignee                                                 |  | Inventors                                                                                                           |  | Assoc.
Tech.
|ACZ.JHV6003   |  | US      |  | PENDING |  | 12/818,380    |  |        |  | 6/18/2010   |  | 9/15/06 - 60/844,830
9/14/07-PCT/US07/078521; 3/16/09 -12/404,891;
11/2/09 - 12/610,798  |  | CYCLOPHOSPHAMIDE IN
COMBINATION WITH ANTI-IDIOTYPIC VACCINES                                                    |  | Johns Hopkins University and Accentia Biopharmaceuticals, Inc. |  | Robert A. Brodsky; Richard J. Jones; Francis E. ODonnell, Jr.; Susan Bonitz; Carlos Santos                         |  | Revimmune   
|              |  |         |  |         |  |               |  |        |  |            
|ACZ.JHV05903  |  | US      |  | PENDING |  | 12/827,773    |  |        |  | 6/30/2010   |  | 9/15/06 - 60/844,829 9/14/07 - PCT/US07/78518 3/16/09 - 12/404,900 11/2/09 - 12/610,756  |  | METHOD OF IDENTIFYING PATIENTS
SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE
TREATMENT                                |  | Johns Hopkins University and Accentia Biopharmaceuticals, Inc. |  | Robert A. Brodsky; Richard J. Jones; Francis E. ODonnell, Jr.; Susan Bonitz; Carlos Santos                         |  | Revimmune   
|              |  |         |  |         |  |               |  |        |  |            
|ACZ.JHV6203   |  | US      |  | PENDING |  | 12/851,110    |  |        |  | 8/05/2010   |  | 11/3/06 - 60/856,698 PCT/US07/081614 - 10/15/07 5/1/09 - 12/434,125 12/14/09 -12/637,177 |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins University and Accentia Biopharmaceuticals, Inc. |  | Robert A. Brodsky; Richard J. Jones; Francis E. ODonnell, Jr.; Susan Bonitz; Carlos Santos                         |  | Revimmune   
|              |  |         |  |         |  |               |  |        |  |            
|ACZ.007CPTCZ1 |  | US      |  | PENDING |  | 12/841,854    |  |        |  | 1/22/2008   |  | 1/22/08 - 61/022,774 8/13/08 - 61/088,570 1/22/09-PCT/US2009/031703                      |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATMENT AND PREVENTION OF TRANSPLANT REJECTION                    |  | Johns Hopkins University and Accentia Biopharmaceuticals, Inc. |  | Robert Brodsky; Richard J. Jones; Susan Bonitz; Francis E. ODonnell, Jr.; Carlos Santos; Ephraim Fuchs; Leo Luznik |  | Revimmune   



1



---

|               |  |         |  |         |  |                  |  |                           |  |             |  |                                                                                                                                                                                               |  |                                                                       |  |                                   |  |                                          |  |             
|-------------- |  | ------- |  | ------- |  | ---------------- |  | ------------------------- |  | ----------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | --------------------------------------------------------------------- |  | --------------------------------- |  | ---------------------------------------- |  | ------------
|Atty Docket #  |  | Country |  | Status  |  | Application #    |  | Pub. #                    |  | Filing
Date |  | Priority                                                                                                                                                                                      |  | Title                                                                 |  | Owner/Assignee                    |  | Inventors                                |  | Assoc.
Tech.
|ACZ.JHV3540AU  |  | AU      |  | PENDING |  | 2006320162       |  |                           |  | 12/04/2006  |  | 12/2/05 - 60/742,172 12/4/06
- PCT/US06/061549                                                                                                                                                |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.JHV3550CA  |  | CA      |  | PENDING |  | 2,631,760        |  |                           |  | 12/04/2006  |  | 12/2/05 - 60/742,172 12/4/06
- PCT/US06/061549                                                                                                                                                |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.JHV3555MX  |  | MX      |  | PENDING |  | Not yet assigned |  |                           |  | 12/04/2006  |  | 12/2/05 - 60/742,172 12/4/06
- PCT/US06/061549                                                                                                                                                |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.JHV3501    |  | US      |  | PENDING |  | 11/566,296       |  | US 2007-0202077
(8/30/07) |  | 12/04/2006  |  | 12/2/05 - 60/742,172                                                                                                                                                                          |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.JHV3501D1  |  | US      |  | PENDING |  | 12/777,729       |  |                           |  | 05/11/2010  |  | 12/2/05 - 60/742,172 12/4/06 -
11/566,296                                                                                                                                                     |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.JHV3580EPO |  | EPO     |  | PENDING |  | 06840105.8       |  |                           |  | 12/04/2006  |  |                                                                                                                                                                                               |  | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS |  | Johns Hopkins
University          |  | Robert Brodsky; Richard Jones            |  | Revimmune   
|               |  |         |  |         |  |                  |  |                           |  |            
|ACZ.100C5XCZ1  |  | US      |  | PENDING |  | 12/785,211       |  |                           |  | 05/21/2010  |  | 11/21/07 - 60/989,
628 3/19/08 - 61/038,033 8/13/08
- 61/088,600 9/10/08 - 61/095,884
09/11/08 -  61/096,232 10/16/08 -
61/106,073 PCT/US2008/084396 -
11/21/08
PCT/US2008 /084414 -
11/21/08 |  | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs |  | Accentia Biopharmaceuticals, Inc. |  | Francis E. ODonnell, Jr.; Carlos Santos |  | Revimmune   



2



---

|              |  |         |  |         |  |               |  |        |  |             |  |                                                                                                                                                                                            |  |                                                                             |  |                                   |  |                                          |  |             
|------------- |  | ------- |  | ------- |  | ------------- |  | ------ |  | ----------- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |  | --------------------------------------------------------------------------- |  | --------------------------------- |  | ---------------------------------------- |  | ------------
|Atty Docket # |  | Country |  | Status  |  | Application # |  | Pub. # |  | Filing
Date |  | Priority                                                                                                                                                                                   |  | Title                                                                       |  | Owner/Assignee                    |  | Inventors                                |  | Assoc. Tech.
|ACZ.100C5XCZ2 |  | US      |  | PENDING |  | 12/785,224    |  |        |  | 05/21/2010  |  | 11/21/07 - 60/989,628
3/19/08 - 61/038,033 8/13/08 -
61/088,600 9/10/08 - 61/095,884
09/11/08 - 61/096,232
10/16/08 - 61/106,073
PCT/US2008/084396 - 11/21/08
PCT/US2008/084414 - 11/21/08 |  | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen |  | Accentia Biopharmaceuticals, Inc. |  | Francis E. ODonnell, Jr.; Carlos Santos |  | Revimmune   
|              |  |         |  |         |  |               |  |        |  |            
|ACZ.100C5XCZ3 |  | US      |  | PENDING |  | 12/789,401    |  |        |  | 05/27/2010  |  | 11/21/07 - 60/989,628 3/19/08
- 61/038,033 8/13/08 - 61/088,600
9/10/08 - 61/095,884 09/11/08 -
61/096,232 10/16/08 - 61/106,073
PCT/US2008/084396 - 11/21/08 PCT/US2008/084414 -
11/21/08 |  | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen |  | Accentia Biopharmaceuticals, Inc. |  | Francis E. ODonnell, Jr.; Carlos Santos |  | Revimmune   

Revimmune

Agreements

1 - Sublicense
Agreement between Revimmune, LLC and Accentia Biopharmaceuticals, Inc., effective February 27, 2007, amended April 18, 2008 and June 16, 2008

2 - License Agreement between Johns Hopkins University and Revimmune, LLC, effective February 20, 2006

3  License Agreement between Accentia Biopharmaceuticals, Inc. and Biovest International, Inc., pending



3



---

Schedule G

FEDERAL ASSIGNMENT OF CLAIMS ACT

None



1



---

ANNEX A

to

SECURITY

AGREEMENT

FORM
OF ADDITIONAL DEBTOR JOINDER

Security Agreement dated as of November 17, 2010 made by

Accentia Biopharmaceuticals, Inc., as Debtor,

to and in favor of

the Secured Parties identified therein (the Security
Agreement)

Reference is made to the Security Agreement as defined above; capitalized terms used
herein and not otherwise defined herein shall have the meanings given to such terms in, or by reference in, the Security Agreement.

The undersigned hereby agrees that upon delivery of this Additional Debtor Joinder to the Secured Parties referred to above, the undersigned shall (a) be an Additional Debtor under the Security
Agreement, (b) have all the rights and obligations of the Debtor under the Security Agreement as fully and to the same extent as if the undersigned was an original signatory thereto, and (c) be deemed to have made the representations and
warranties set forth in the Security Agreement as of the date of execution and delivery of this Additional Debtor Joinder. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE UNDERSIGNED SPECIFICALLY GRANTS TO THE SECURED PARTIES A SECURITY
INTEREST IN THE COLLATERAL AS MORE FULLY SET FORTH IN THE SECURITY AGREEMENT AND ACKNOWLEDGES AND AGREES TO THE WAIVER OF JURY TRIAL PROVISIONS SET FORTH THEREIN.

Attached hereto are supplemental and/or replacement Disclosure Schedules to the Security Agreement, as applicable.

An executed copy of this Additional Debtor Joinder shall be delivered to the Secured Parties, and the Secured
Parties may rely on the matters set forth herein on or after the date hereof. This Additional Debtor Joinder shall not be modified, amended or terminated without the prior written consent of the Secured Parties.



---

IN WITNESS WHEREOF, the undersigned has caused this Additional Debtor
Joinder to be executed in the name and on behalf of the undersigned.



[Name of Additional Debtor]By:Name:Title:Address:


Date:



---

ANNEX B

to

SECURITY

AGREEMENT

THE
AGENT

1. Appointment. The Secured Parties (all capitalized terms used herein and not otherwise defined shall
have the respective meanings provided in the Security Agreement to which this Annex B is attached (the Agreement)), by their acceptance of the benefits of the Agreement, hereby designate Midsummer Investment Ltd.
(Midsummer or Agent) as the Agent to act as specified herein and in the Agreement. Each Secured Party shall be deemed irrevocably to authorize the Agent to take such action on its behalf under the provisions of
the Agreement and to exercise such powers and to perform such duties hereunder and thereunder as are specifically delegated to or required of the Agent by the terms hereof and thereof and such other powers as are reasonably incidental thereto. The
Agent may perform any of its duties hereunder by or through its agents or employees.

2. Nature of Duties. The
Agent shall have no duties or responsibilities except those expressly set forth in the Agreement. Neither the Agent nor any of its partners, members, shareholders, officers, directors, employees or agents shall be liable for any action taken or
omitted by it as such under the Agreement or hereunder or in connection herewith or therewith, be responsible for the consequence of any oversight or error of judgment or answerable for any loss, unless caused solely by its or their gross negligence
or willful misconduct as determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction. The duties of the Agent shall be mechanical and administrative in nature; the Agent shall not have by reason of the
Agreement or any other Transaction Document a fiduciary relationship in respect of the Debtor or any Secured Party; and nothing in the Agreement or any other Transaction Document, expressed or implied, is intended to or shall be so construed as to
impose upon the Agent any obligations in respect of the Agreement or any other Transaction Document except as expressly set forth herein and therein.

3. Lack of Reliance on the Agent. Independently and without reliance upon the Agent, each Secured Party, to the extent it deems appropriate, has made and shall continue to make (i) its own
independent investigation of the financial condition and affairs of the Company and its subsidiaries in connection with such Secured Partys investment in the Company, the creation and continuance of the Obligations, the transactions
contemplated by the Transaction Document, and the taking or not taking of any action in connection therewith, and (ii) its own appraisal of the creditworthiness of the Company and its subsidiaries, and of the value of the Collateral from time
to time, and the Agent shall have no duty or responsibility, either initially or on a continuing basis, to provide any Secured Party with any credit, market or other information with respect thereto, whether coming into its possession before any
Obligations are incurred or at any time or times thereafter. The Agent shall not be responsible to the Debtor or any



---

Secured Party for any recitals, statements, information, representations or warranties herein or in any document, certificate or other writing delivered in connection herewith, or for the
execution, effectiveness, genuineness, validity, enforceability, perfection, collectibility, priority or sufficiency of the Agreement or any other Transaction Document, or for the financial condition of the Debtor or the value of any of the
Collateral, or be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of the Agreement or any other Transaction Document, or the financial condition of the Debtor, or the value
of any of the Collateral, or the existence or possible existence of any default or Event of Default under the Agreement or any other Transaction Document.

4. Certain Rights of the Agent. The Agent shall have the right to take any action with respect to the Collateral, on behalf of all of the Secured Parties. To the extent practical, the Agent shall request
instructions from the Secured Parties with respect to any material act or action (including failure to act) in connection with the Agreement or any other Transaction Document, and shall be entitled to act or refrain from acting in accordance with
the instructions of a Majority in Interest; if such instructions are not provided despite the Agents request therefor, the Agent shall be entitled to refrain from such act or taking such action, and if such action is taken, shall be entitled
to appropriate indemnification from the Secured Parties in respect of actions to be taken by the Agent; and the Agent shall not incur liability to any person or entity by reason of so refraining. Without limiting the foregoing, (a) no Secured
Party shall have any right of action whatsoever against the Agent as a result of the Agent acting or refraining from acting hereunder in accordance with the terms of the Agreement or any other Transaction Document, and the Debtor shall have no right
to question or challenge the authority of, or the instructions given to, the Agent pursuant to the foregoing and (b) the Agent shall not be required to take any action which the Agent believes (i) could reasonably be expected to expose it
to personal liability or (ii) is contrary to this Agreement, the Debentures, any other Transaction Document or applicable law.

5. Reliance. The Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, resolution, notice, statement, certificate, telex, teletype or telecopier message, cablegram,
radiogram, order or other document or telephone message signed, sent or made by the proper person or entity, and, with respect to all legal matters pertaining to the Agreement, the Debentures and any other Transaction Document and its duties
thereunder, upon advice of counsel selected by it and upon all other matters pertaining to this Agreement and the Debentures and any other Transaction Document and its duties thereunder, upon advice of other experts selected by it. Anything to the
contrary notwithstanding, the Agent shall have no obligation whatsoever to any Secured Party to assure that the Collateral exists or is owned by the Debtor or is cared for, protected or insured or that the liens granted pursuant to the Agreement
have been properly or sufficiently or lawfully created, perfected, or enforced or are entitled to any particular priority.

6. Indemnification. To the extent that the Agent is not reimbursed and indemnified by the Debtor, the Secured Parties will jointly and severally reimburse and



---

indemnify the Agent, in proportion to their initially purchased respective principal amounts of Debentures, from and against any and all liabilities, obligations, losses, damages, penalties,
actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever which may be imposed on, incurred by or asserted against the Agent in performing its duties hereunder or under the Agreement or any other Transaction
Document, or in any way relating to or arising out of the Agreement or any other Transaction Document except for those determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction to have resulted solely from
the Agents own gross negligence or willful misconduct. Prior to taking any action hereunder as Agent, the Agent may require each Secured Party to deposit with it sufficient sums as it determines in good faith is necessary to protect the Agent
for costs and expenses associated with taking such action.

7. Resignation by the Agent.

(a) The Agent may resign from the performance of all its functions and duties under the Agreement and the
other Transaction Documents at any time by giving 30 days prior written notice (as provided in the Agreement) to the Debtor and the Secured Parties. Such resignation shall take effect upon the appointment of a successor Agent pursuant to
clauses (b) and (c) below.

(b) Upon any such notice of resignation, the Secured
Parties, acting by a Majority in Interest, shall appoint a successor Agent hereunder.

(c) If a
successor Agent shall not have been so appointed within said 30-day period, the Agent shall then appoint a successor Agent who shall serve as Agent until such time, if any, as the Secured Parties appoint a successor Agent as provided above. If a
successor Agent has not been appointed within such 30-day period, the Agent may petition any court of competent jurisdiction or may interplead the Debtor and the Secured Parties in a proceeding for the appointment of a successor Agent, and all fees,
including, but not limited to, extraordinary fees associated with the filing of interpleader and expenses associated therewith, shall be payable by the Debtor on demand.

8. Rights With Respect to Collateral. Each Secured Party agrees with all other Secured Parties and the Agent
(i) that it shall not, and shall not attempt to, exercise any rights with respect to its security interest in the Collateral, whether pursuant to any other agreement or otherwise (other than pursuant to the Agreement), or take or institute any
action against the Agent or any of the other Secured Parties in respect of the Collateral or its rights hereunder (other than any such action arising from the breach of the Agreement) and (ii) that such Secured Party has no other rights with
respect to the Collateral other than as set forth in the Agreement. Upon the acceptance of any appointment as Agent hereunder by a successor Agent, such successor Agent shall thereupon succeed to and become vested with all the rights, powers,
privileges and duties of the retiring Agent and the retiring Agent shall be discharged from its duties and obligations under the Agreement. After any retiring Agents resignation or removal



---

hereunder as Agent, the provisions of the Agreement including this Annex B shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent.